MedTrace Logo

Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus

NCT00232362 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-04-13

No results posted yet for this study

Summary

This study is being done to determine if pioglitazone (Actos) is helpful to patients with type 2 diabetes and could possibly prevent harmful consequences of cardiovascular disease in diabetic patients.

Conditions

Interventions

DRUG

Pioglitazone (Actos)

DRUG

Anti-diabetic agent other than pioglitazone or rosiglitazone

Sponsors & Collaborators

  • Texas Tech University Health Sciences Center

    lead OTHER

Principal Investigators

  • Chanwit Roongsritong, MD · TTUHSC

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Completion
2008-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232362 on ClinicalTrials.gov